Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Hemophilia (Jun 2017)

Posted by Matt Breese on Jun 21, 2017

Find me on:

According to our recent payer coverage analysis for hemophilia treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for hemophilia treatments shows the complex dynamics of pharmacy and medical benefit coverage across payer-controlled formularies. While the pharmacy benefit includes a greater percentage of "not covered" lives, PAs and step edits are prevalent for medical benefit.


Data current as of Q2 2017 

Trends: A recent article from highlights a Hemophilia patient in Iowa that has a treatment cost of $1,000,000 per month. This story is just one data point in the larger debate around improving healthcare costs - specifically by separating high-risk patients from the general population.

To read the full Reality Check on Hemophilia treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing